https://www.selleckchem.com/products/bay-876.html
The present study showed the involvement of immunosuppressive myeloid-derived suppressor cells during the disease progression in a 69-year-old man with a prostate cancer. The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy for 5months and then chemotherapy with docetaxel, but he expired at the 8th month. In order to investigate whether myeloid-derived suppressor cells are implicated in the cancer exacerbation during androgen deprivation therapy, we assessed the long-term changes in
Like
Comment
Share
